[go: up one dir, main page]

UA108980C2 - Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality - Google Patents

Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality

Info

Publication number
UA108980C2
UA108980C2 UAA201013631A UAA201013631A UA108980C2 UA 108980 C2 UA108980 C2 UA 108980C2 UA A201013631 A UAA201013631 A UA A201013631A UA A201013631 A UAA201013631 A UA A201013631A UA 108980 C2 UA108980 C2 UA 108980C2
Authority
UA
Ukraine
Prior art keywords
dronedarone
prevention
mortality
medicament
preparation
Prior art date
Application number
UAA201013631A
Other languages
Ukrainian (uk)
Inventor
Christophe Gaudin
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Priority claimed from PCT/IB2009/005587 external-priority patent/WO2009144550A2/en
Publication of UA108980C2 publication Critical patent/UA108980C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід стосується способу профілактики серцево-судинних госпіталізацій, що включає введення дронедарону або його фармацевтично прийнятних солей в дозі 800 мг, яку приймають в один або більше прийомів під час сніданку та ввечері, де вказаний лікарський засіб протипоказаний для хворих з тяжкою серцевою недостатністю.The invention relates to a method for the prevention of cardiovascular hospitalizations, including the introduction of dronedarone or its pharmaceutically acceptable salts at a dose of 800 mg, which is taken in one or more receptions during breakfast and evening, where the specified drug is contraindicated for patients with severe heart failure.

UAA201013631A 2008-04-17 2009-04-16 Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality UA108980C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0802127A FR2930148A1 (en) 2008-04-17 2008-04-17 Use of dronedarone to prepare medicament to prevent mortality and/or cardiovascular hospitalizations in patients having e.g. history of atrial fibrillation/atrial flutter, cerebrovascular accident and non-rheumatic valvular heart disease
PCT/IB2009/005587 WO2009144550A2 (en) 2008-04-17 2009-04-16 Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality

Publications (1)

Publication Number Publication Date
UA108980C2 true UA108980C2 (en) 2015-07-10

Family

ID=39940579

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201013631A UA108980C2 (en) 2008-04-17 2009-04-16 Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality

Country Status (2)

Country Link
FR (1) FR2930148A1 (en)
UA (1) UA108980C2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3195862A1 (en) * 2008-04-17 2017-07-26 Sanofi Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation
FR2930150B1 (en) * 2008-06-24 2011-01-14 Sanofi Aventis USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM RATE IN BLOOD
WO2011158178A1 (en) * 2010-06-14 2011-12-22 Sanofi Use of dronedarone for the preparation of a medicament for use in the treatment of patients
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2746013B1 (en) * 1996-03-18 1998-05-29 Sanofi Sa USE OF ANTIARRHYTHMIC COMPOUNDS IN THE PREVENTION OF POST INFARCT MORTALITY

Also Published As

Publication number Publication date
FR2930148A1 (en) 2009-10-23

Similar Documents

Publication Publication Date Title
EA201071204A1 (en) DRONEDARON APPLICATION FOR THE PREPARATION OF A MEDICINE FOR THE APPLICATION IN THE PREVENTION OF HOSPITALIZATION IN THE CARDIOLOGICAL DEPARTMENT OR MORTALITY
JP2015515475A5 (en)
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
EA200901423A1 (en) BENZIMIDAZOLY AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
MX339614B (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2.
JP2012517449A5 (en)
FI4321157T3 (en) New use of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi)
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
BR112012016783A2 (en) "Uses of the naltrexone compound or pharmaceutically acceptable salt thereof to bupropion or pharmaceutically acceptable salt thereof or composition thereof and methods for providing therapy"
JP2013166781A5 (en)
UA108980C2 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
MX363389B (en) Pharmaceutical composition comprising amorphous ivabradine.
UA100883C2 (en) Use of dronedarone or one of its pharmaceutically acceptable salts for preparing a medicament for the treatment of patients with arrhythmia and an increased creatinine level due to dronedarone administration
MX2010005008A (en) Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs.
JP2013032308A5 (en)
UA109544C2 (en) PHARMACEUTICAL COMPOSITION CONTAINING PARACETAMOL AND METHOD OF MANUFACTURING
AR075866A1 (en) A DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL DETERIORATION. USE. PHARMACEUTICAL COMPOSITION
MX2010011401A (en) Combination of dronedarone with at least one diuretic, and therapeutic use thereof.
WO2010098625A2 (en) Pharmaceutical preparation
JP2012097034A5 (en)
JP2016505628A5 (en)
AR081031A1 (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY IN PA-HUNDREDS WHO HAVE A FIRST RECURRENCE OF HEADPHONES OR ALE-TEO HEADPHONES
Marfatia et al. Effects of Telmisartan with Hydrochlorothiazide versus Valsartan with Hydrochlorothiazide in Patients with Moderate‐to‐Severe Hypertension
Imai Peripheral neuritis: case report